Which dose of busulfan is best?

Clinical Chemistry

Volumn 56, Issue 7, 2010, Pages 1061-1064

  Johnson Davis, Kamisha L ^a   McMillin, Gwendolyn A ^a,c   Juenke, JoEtta M ^c   Ford, Clyde D ^b   Petersen, Finn B ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN;

ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; YOUNG ADULT;

EID: 77954377098     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.134940     Document Type: Article

References (10)

1. Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res 1993;53:1534-7.
2. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following HSCT. Bone Marrow Transplant 1996;17:225-30.
3. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20:18-25.
4. Tran HT, Madden T, Petropoulos D, Worth LL, Feliz EA, Sprigg-Saenz HA, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000;26:463-70.
5. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999;12:4436-40. (Pubitemid 29279287)
6. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, et al. Pharmacokinetics and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989;36:525-30. (Pubitemid 19135219)
7. Krivoy N, Hoffer E, Tabak A, Elhasid R, Arush MW, Stein J, et al. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation. Pediatr Hematol Oncol 2002;19:31-7. (Pubitemid 34665491)
8. Nilsson C, Aschan J, Hentschke P, Ringdén O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:429-35. (Pubitemid 36511807)
9. Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D, for the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007;41:755-63.
10. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haemotopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191-8.